Category: Value in Health Regional Issues

Scientific journal of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) published up to three times a year with one issue focusing on the Asian region, one issue focusing on the Latin American region, and one issue focusing on the Central & Eastern Europe, Western Asia and African region.

IS PAYERS’ DATABASE SUITABLE FOR CANCER SERVICE EVALUATION?

Budapest, Hungary – Malignant diseases represent a high burden for societies in Central and Eastern European countries. The data routinely collected in the database of the Hungarian National Health Insurance Fund can be used to assess some quality indicators related

Posted in Health Policy Analyses, ISPOR News & Press, Value in Health Regional Issues Tagged with: , ,

THE FOURTH HURDLE – CAN IT BE SIMPLIFIED?

Melbourne, Australia – While regulatory systems are well established within Asia-Pacific countries, formalised health technology assessment (HTA) based reimbursement systems are relatively new, yet rapidly evolving. Closer understanding of the different reimbursement processes within Asia-Pacific can allow for best-practice cross-pollination, leading

Posted in Health Policy Analyses, Value in Health Regional Issues Tagged with: , , ,

TREATMENT PREFERENCES FOR BLOOD THINNERS: COMPARISON BETWEEN PHYSICIANS AND PATIENTS WITH ATRIAL FIBRILLATION IN THE U.S. AND JAPAN

Hirosaki, Japan – Blood thinners (anticoagulants) are crucial in preventing strokes among patients with atrial fibrillation (AF) but are associated with increased risk of bleeding. As described in the article, “Comparing Patient and Physician Risk Tolerance for Bleeding Events Associated with

Posted in Preference-Based Assessments, Value in Health Regional Issues Tagged with: , , ,

THE PROBLEM OF REIMBURSEMENT FOR SINGLE-USE DEVICES IN ASIA-PACIFIC COUNTRIES

Seoul, South Korea – In Asia-Pacific countries, as elsewhere, less than 6% of total health care spending per capita is on medical devices, though these technologies often make critical contributions to the delivery of clinical and economic benefits to both

Posted in ISPOR News & Press, Policy Perspectives, Value in Health Regional Issues Tagged with: , , ,

ENSURING THE FUTURE FOR CHINA’S ESSENTIAL DRUG POLICY

New Orleans, LA, USA & Shandong, China – China is one of the few middle-income countries with higher pharmaceutical cost out of total health care spending. The primary purpose of China’s National Essential Drug Policy (NEDP) in year 2009 was

Posted in Health Policy Analyses, Value in Health Regional Issues Tagged with: , , ,

ASSURE SAFETY IN INTRAVENOUS MEDICATION USE IN CHINA

Beijing, China – Chinese inpatients have experienced overuse of intravenous medications, with a total of 10.4 billion infusion bottles for 1.3 billion Chinese people annually, approximately 8 infusion bottles per capita in 2009. However, few studies have yet been published

Posted in Comparative Effectiveness Research / Health Technology Assessment, ISPOR News & Press, Value in Health Regional Issues Tagged with: , , ,